SEPTInvestingStart Free

BBOT SCHEDULE 13G/A: SEC filing

Deerfield entities and James E. Flynn

Filed with the SEC on · accession 0001193805-26-001463

BBOT filed a SCHEDULE 13G/A (schedule 13g/a) with the SEC on Nov 13, 2026. Deerfield entities and James E. Flynn filed an amended Schedule 13G reporting beneficial ownership of approximately 3.91% of BridgeBio Oncology Therapeutics common stock, a passive investment position. The stock moved -8.9% by the first close after the filing.

Summary of the filing

Deerfield entities and James E. Flynn filed an amended Schedule 13G reporting beneficial ownership of approximately 3.91% of BridgeBio Oncology Therapeutics common stock, a passive investment position. The filing indicates no intent to influence control of the company.

For details, click here →

Key details

Shares beneficially owned by Deerfield Management Company, L.P. and James E. Flynn$3.1M
Shares beneficially owned by Deerfield Mgmt, L.P. and Deerfield Partners, L.P.$1.6M
Shares beneficially owned by Deerfield Mgmt V, L.P. and Deerfield Private Design Fund V, L.P.$1.6M
Reporting person / investment advisorDeerfield Management Company, L.P.
Reporting person / shareholderDeerfield Partners, L.P.
Reporting person / shareholderDeerfield Private Design Fund V, L.P.
IssuerBridgeBio Oncology Therapeutics, Inc.
Reporting person / control person of deerfield entitiesJames E. Flynn

How BBOT stock reacted

Close before

$2.35

Nov 12, 2026

First close after

-8.94%

$2.14

5 trading days

—

Since filing

—

✦ Ask GOAX AI about this filing — what it means for BBOT, what changed since its last filings and what to watch next.

Try it free for 7 days

🔔 Want to stay updated on new SEC filings for BBOT?

Click here

Frequently asked questions

What did BBOT file with the SEC on Nov 13, 2026?

BBOT filed a SCHEDULE 13G/A (SEC filing). Deerfield entities and James E. Flynn filed an amended Schedule 13G reporting beneficial ownership of approximately 3.91% of BridgeBio Oncology Therapeutics common stock, a passive investment position. The filing indicates no intent to influence control of the company.

How do I read a SCHEDULE 13G/A?

A report the company filed with the SEC (the US market regulator). Start with the summary, then the key amounts and names. Compare it with the company’s earlier filings.

Why are SEC filings important?

Public companies must tell the SEC about anything that can change their value — results, leadership changes, big deals, new shares, bankruptcy. Filings are the official source, often before the news. A SCHEDULE 13G/A (schedule 13g/a): A report the company filed with the SEC (the US market regulator).

How did BBOT stock react to this filing?

BBOT closed at $2.35 before the filing and $2.14 on Nov 13, 2026 (-8.94%).

Other BBOT SEC filings

Get alerts when BBOT files with the SEC, plus live charts, key levels and news for 13,000+ stocks.

Try SEPT free for 7 days
BBOT overviewBBOT analysisBBOT newsLatest SEC filings